A PHASE I SAFETY AND PHARMACOKINETIC STUDY OF EVEROLIMUS, AN ORAL MTOR INHIBITOR, IN SUBJECTS WITH IMPAIRED HEPATIC FUNCTION Article Peveling-Oberhag J., Zeuzem S., Yong W.P., Kunz T., Paquet T., Bouillaud E., Urva S., Anak O., Sellami D., Kobalava Z. EUROPEAN JOURNAL OF CANCER. ELSEVIER SCI LTD. Vol. 47. 2011.
INFLAMMATION RESEARCH Conference proceedings 40th Annual Meeting of the European-Histamine-Research-Society. SPRINGER BASEL AG.